16/12/20 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
14/12/20 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
17/11/20 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
17/11/20 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
17/11/20 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
President 59 -
Director TitleAgeSince
Director/Board Member 59 -
Director/Board Member - -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
16/11/20 Issuer sale

Director

131,728 0.3818%
16/11/20 Issuer sale

Chief Financial Officer

41,038 0.1189%
16/11/20 Issuer sale

Chairman

136,253 0.3949%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
+6.69%+5.07%+68.77%+142.70% 1,148B
+1.25%+2.73%+47.33%+86.98% 652B
+1.11%+1.44%+28.50%+103.89% 505B
+0.80%+2.52%+54.38%+66.60% 384B
+4.86%+0.24%+70.47%+43.74% 348B
+2.56%+2.81%+34.52%+56.56% 294B
+2.37%+0.62%+3.98%+27.81% 264B
+1.43%+2.62%+57.32%+74.40% 244B
+1.27%+2.63%+36.14%+107.44% 197B
Average +2.24%+1.39%+44.60%+78.90% 448.57B
Weighted average by Cap. +3.20%+1.50%+50.03%+93.44%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock